Biospecifics Technologies Corp., of Lynbrook, N.Y., said Swedish Orphan Biovitrum AB (Sobi), of Stockholm, received approval from the EC to market Xiapex (collagenase clostridium histolyticum or CCH) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.